Firmagon 2014 U.S. PROMOTIONAL AUDIT REPORT

Published July 2015 • 20 Pages

The 5 Key Questions Addressed by this Report:

• How many physicians were reached by Firmagon through personal promotion in 2014 and how does this compare to its peer set in the Prostate Cancer market?
• What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
• How does Ferring’s depth of coverage vary within key specialties (e.g., Urology and Hematology/Oncology) and how does this compare to its peers and the overall set of rep-accessible physicians?
• How often are physicians receiving paid meals for Firmagon throughout the year (e.g., monthly, quarterly, annually)?
• Who were the most detailed prescribers and top paid speakers/consultants for Firmagon in 2014?

Data Sources and Methodology:

• MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
• Over 8,200 paid interactions across 2,900 physicians made on behalf of Firmagon were carefully examined to support our analysis. In addition, interaction data from 7 peer products (e.g. Eligard, Jevtana, Lupron Depot, Trelstar, Xofigo, Xtandi, and Zytiga) was leveraged to provide benchmarking and market insights.